Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.

The New England Journal of Medicine
Mathew S MaurerATTR-ACT Study Investigators

Abstract

Transthyretin amyloid cardiomyopathy is caused by the deposition of transthyretin amyloid fibrils in the myocardium. The deposition occurs when wild-type or variant transthyretin becomes unstable and misfolds. Tafamidis binds to transthyretin, preventing tetramer dissociation and amyloidogenesis. In a multicenter, international, double-blind, placebo-controlled, phase 3 trial, we randomly assigned 441 patients with transthyretin amyloid cardiomyopathy in a 2:1:2 ratio to receive 80 mg of tafamidis, 20 mg of tafamidis, or placebo for 30 months. In the primary analysis, we hierarchically assessed all-cause mortality, followed by frequency of cardiovascular-related hospitalizations according to the Finkelstein-Schoenfeld method. Key secondary end points were the change from baseline to month 30 for the 6-minute walk test and the score on the Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS), in which higher scores indicate better health status. In the primary analysis, all-cause mortality and rates of cardiovascular-related hospitalizations were lower among the 264 patients who received tafamidis than among the 177 patients who received placebo (P<0.001). Tafamidis was associated with lower all-cause mortality tha...Continue Reading

References

Nov 14, 1997·Journal of Biopharmaceutical Statistics·R D Wolfinger
Jul 10, 1999·Statistics in Medicine·D M Finkelstein, D A Schoenfeld
Apr 12, 2000·Journal of the American College of Cardiology·C P GreenJ A Spertus
Dec 29, 2000·Journal of the American College of Cardiology·B A GroenningP R Hildebrandt
Sep 29, 2001·Science·P HammarströmJ W Kelly
Jul 2, 2002·American Journal of Respiratory and Critical Care Medicine·UNKNOWN ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories
May 19, 2010·Nature Reviews. Cardiology·Claudio RapezziAngelo Branzi
Sep 6, 2012·Circulation·Frederick L Ruberg, John L Berk
Jan 25, 2014·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·Andor W J M GlaudemansBouke P C Hazenberg
Aug 1, 2015·European Heart Journal·Esther González-LópezPablo Garcia-Pavia
Oct 16, 2015·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·Arnault GalatThibaud Damy
May 5, 2016·Circulation·Julian D GillmorePhilip N Hawkins
Jul 9, 2016·Journal of the American College of Cardiology·Mathew S MaurerUNKNOWN THAOS Investigators
Aug 29, 2016·JACC. Cardiovascular Imaging·Muhammad HaqFrederick L Ruberg
Sep 3, 2016·Journal of the American College of Cardiology·Martha GroganAngela Dispenzieri
Apr 11, 2017·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·Denis KeohaneLeslie Amass
Jun 15, 2017·Circulation. Heart Failure·Mathew S MaurerUNKNOWN ATTR-ACT Study Investigators
Sep 28, 2017·Clinical Medicine Insights. Cardiology·Marla B SultanJeffrey H Schwartz

❮ Previous
Next ❯

Citations

Aug 28, 2018·The New England Journal of Medicine·C Cristina Quarta, Scott D Solomon
Nov 28, 2018·Neurodegenerative Disease Management·Arnt V KristenLaura Obici
Dec 19, 2018·Neurodegenerative Disease Management·Merrill D BensonBrett P Monia
Dec 28, 2018·European Heart Journal·Brian P Halliday, Dudley J Pennell
Jan 3, 2019·European Heart Journal·Wojciech Wojakowski, Helmut Baumgartner
Jan 10, 2019·The New England Journal of Medicine
Jan 22, 2019·Circulation·Sanjiv J Shah
Feb 1, 2019·Journal of Thrombosis and Thrombolysis·Dylan L Steen
Feb 16, 2019·Future Cardiology·Massimiliano Lorenzini, Perry M Elliott
Feb 20, 2019·European Heart Journal·John G F ClelandPiotr Ponikowski
Dec 28, 2018·Chembiochem : a European Journal of Chemical Biology·Marcus J C LongYimon Aye
Apr 9, 2019·European Heart Journal·Filippos TriposkiadisGilles W De Keulenaer
Apr 17, 2019·European Journal of Heart Failure·Petar M SeferovićCarsten Tschöpe
Apr 24, 2019·JAMA : the Journal of the American Medical Association·Jerry H Gurwitz, Steven D Pearson
Feb 23, 2019·Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology·Vasvi SinghSaurabh Malhotra
May 24, 2019·Circulation Research·Marc A PfefferBarry A Borlaug
May 24, 2019·Circulation Research·Giuliana G RepettiChristine E Seidman
May 11, 2019·Protein Science : a Publication of the Protein Society·Kristine Faye R PobreEvan T Powers
May 28, 2019·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·F EscherG Poelzl
Jun 8, 2019·Circulation. Heart Failure·Jan M Griffin, Mathew S Maurer
Jul 4, 2019·Expert Review of Clinical Pharmacology·Morie A GertzLaura Obici
Jul 25, 2019·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·Isabel ConceiçãoAntoine Rousseau
Jul 25, 2019·European Journal of Heart Failure·Marco CanepaStefano Perlini
Jun 8, 2019·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·Nikita PatilAmbarish Pandey
Jul 17, 2019·Clinical Transplantation·Michelle M KittlesonJaime D Moriguchi
Aug 2, 2019·Brain and Behavior·Morie A GertzTeresa Coelho
Sep 11, 2019·Annals of Clinical and Translational Neurology·Yo-Tsen LiuTsyr-Yan Yu
Sep 23, 2018·Blood·Cindy VargaRaymond L Comenzo
Nov 2, 2019·International Heart Journal·Takeshi NehashiYasuchika Takeishi
Oct 23, 2019·Muscle & Nerve·Haruki Koike, Masahisa Katsuno
Oct 1, 2019·Expert Opinion on Pharmacotherapy·Paolo MilaniLaura Obici
Sep 2, 2019·Current Treatment Options in Cardiovascular Medicine·Agostina M FavaMilind Y Desai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiac Amyloidosis

Cardiac amyloidosis is a myocardial disease characterized by extracellular amyloid infiltration throughout the heart. Discover the latest research on cardiac amyloidosis here.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Related Papers

The New England Journal of Medicine
Merrill D BensonTeresa Coelho
The New England Journal of Medicine
Robert J MayerRECOURSE Study Group
The New England Journal of Medicine
Alain RavaudS-TRAC Investigators
The New England Journal of Medicine
Dennis M BlackHORIZON Pivotal Fracture Trial
The New England Journal of Medicine
James LarkinAntoni Ribas
© 2022 Meta ULC. All rights reserved